Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
$6.44
-0.3%
$6.02
$3.06
$6.76
$1.47B0.462.63 million shs1.53 million shs
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$9.39
-7.9%
$15.83
$7.10
$29.70
$194.84M0.84249,470 shs838,744 shs
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$1.16
-4.9%
$1.57
$1.15
$8.70
$18.24M1.2987,161 shs47,086 shs
Immatics stock logo
IMTX
Immatics
$9.78
-3.6%
$11.40
$6.46
$13.16
$827.98M0.67488,139 shs685,196 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$7.29
-1.2%
$7.14
$1.62
$9.00
$349.05M0.9185,302 shs107,354 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
-1.22%+6.95%+1.10%+27.17%+93.99%
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-7.36%-10.22%-31.84%+13.85%+23.95%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-0.81%-3.17%-19.21%-36.13%-83.06%
Immatics stock logo
IMTX
Immatics
-2.59%-0.78%-10.26%-13.47%+47.96%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+1.65%+9.33%-6.94%+48.19%+196.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
2.5628 of 5 stars
2.63.00.00.02.22.51.9
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
3.7872 of 5 stars
3.51.00.04.82.42.50.0
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
2.6674 of 5 stars
3.55.00.00.02.80.00.6
Immatics stock logo
IMTX
Immatics
N/AN/AN/AN/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
1.7293 of 5 stars
3.53.00.00.01.81.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
3.25
Buy$7.8822.28% Upside
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
3.00
Buy$34.67269.19% Upside
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3.00
Buy$19.801,606.90% Upside
Immatics stock logo
IMTX
Immatics
3.00
BuyN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$12.5071.47% Upside

Current Analyst Ratings

Latest ADVM, TCRX, APTO, IMTX, and ADMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00
4/17/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$10.00
4/3/2024
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$5.00
3/27/2024
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
3/26/2024
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $7.50
3/19/2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/7/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
3/6/2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$9.00 ➝ $10.00
3/1/2024
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
2/29/2024
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$6.50 ➝ $8.00
2/29/2024
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
$258.21M5.69$0.05 per share128.70$0.60 per share10.73
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$3.60M54.12N/AN/A$8.26 per share1.14
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
Immatics stock logo
IMTX
Immatics
$58.44M14.17N/AN/A$2.88 per share3.40
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$21.05M16.58N/AN/A$3.15 per share2.31

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
-$28.24M-$0.13N/A12.88N/A-10.94%0.49%0.21%5/8/2024 (Estimated)
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)
Immatics stock logo
IMTX
Immatics
-$104.98M-$1.30N/AN/AN/A-179.67%-43.58%-22.38%5/21/2024 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$89.22M-$1.89N/AN/AN/A-423.86%-60.65%-33.86%5/8/2024 (Estimated)

Latest ADVM, TCRX, APTO, IMTX, and ADMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$1.48-$1.44+$0.04-$1.44N/AN/A
3/21/2024Q4 2023
Immatics stock logo
IMTX
Immatics
-$0.41-$0.32+$0.09-$0.32$11.78 million$17.14 million
3/18/2024Q4 2023
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$2.80-$2.30+$0.50-$2.30N/AN/A
3/6/202412/31/2023
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.29-$0.21+$0.08-$0.21$2.94 million$7.21 million
2/28/2024Q4 2023
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
$0.02$0.04+$0.02$0.16$73.50 million$73.90 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
Immatics stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
1.04
5.16
1.69
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
4.13
4.13
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
0.78
0.78
Immatics stock logo
IMTX
Immatics
N/A
2.87
2.87
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.18
6.51
6.51

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
75.68%
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
Immatics stock logo
IMTX
Immatics
64.41%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics, Inc. stock logo
ADMA
ADMA Biologics
624228.22 million214.53 millionOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
12120.75 million19.66 millionOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3115.72 million14.22 millionNo Data
Immatics stock logo
IMTX
Immatics
43284.66 million81.86 millionOptionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
15447.88 million43.92 millionNot Optionable

ADVM, TCRX, APTO, IMTX, and ADMA Headlines

SourceHeadline
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingTScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
globenewswire.com - April 24 at 4:05 PM
TScan Therapeutics Announces Exercise of Underwriters Option to Purchase Additional SharesTScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com - April 24 at 11:03 AM
TScan Therapeutics (NASDAQ:TCRX) Receives Outperform Rating from WedbushTScan Therapeutics (NASDAQ:TCRX) Receives Outperform Rating from Wedbush
americanbankingnews.com - April 24 at 4:48 AM
Unveiling 4 Analyst Insights On TScan TherapeuticsUnveiling 4 Analyst Insights On TScan Therapeutics
markets.businessinsider.com - April 23 at 4:35 PM
TScan Therapeutics (TCRX) Outperform Rating Reaffirmed at WedbushTScan Therapeutics' (TCRX) Outperform Rating Reaffirmed at Wedbush
marketbeat.com - April 23 at 1:49 PM
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingTScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
globenewswire.com - April 22 at 5:01 PM
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And BeyondSimplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond
seekingalpha.com - April 22 at 1:58 PM
Research Analysts Set Expectations for TScan Therapeutics, Inc.s Q1 2024 Earnings (NASDAQ:TCRX)Research Analysts Set Expectations for TScan Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TCRX)
americanbankingnews.com - April 20 at 1:30 AM
TScan Therapeutics Announces Closing of Upsized Public OfferingTScan Therapeutics Announces Closing of Upsized Public Offering
globenewswire.com - April 19 at 10:05 AM
Wedbush Equities Analysts Reduce Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX)Wedbush Equities Analysts Reduce Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX)
marketbeat.com - April 19 at 8:16 AM
Brokers Set Expectations for TScan Therapeutics, Inc.s Q1 2025 Earnings (NASDAQ:TCRX)Brokers Set Expectations for TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX)
americanbankingnews.com - April 19 at 3:01 AM
TScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by WedbushTScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by Wedbush
americanbankingnews.com - April 19 at 1:58 AM
Wedbush Comments on TScan Therapeutics, Inc.s Q1 2025 Earnings (NASDAQ:TCRX)Wedbush Comments on TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX)
marketbeat.com - April 18 at 6:31 AM
TScan launches $125 million public stock offeringTScan launches $125 million public stock offering
investing.com - April 18 at 12:57 AM
TScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by WedbushTScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by Wedbush
marketbeat.com - April 17 at 3:51 PM
TScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesTScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
finanznachrichten.de - April 17 at 9:55 AM
TScan Therapeutics Announces Pricing Of Public Offering - Quick FactsTScan Therapeutics Announces Pricing Of Public Offering - Quick Facts
markets.businessinsider.com - April 17 at 9:55 AM
TScan Therapeutics Announces Pricing of Upsized $150 Million Public OfferingTScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
finance.yahoo.com - April 17 at 9:55 AM
TScan Therapeutics Announces Launch of $125 Million Proposed Public OfferingTScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
finance.yahoo.com - April 16 at 7:19 PM
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesTScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
globenewswire.com - April 16 at 4:01 PM
TScan Therapeutics Appoints Chrystal Louis As Chief Medical Officer - Quick FactsTScan Therapeutics Appoints Chrystal Louis As Chief Medical Officer - Quick Facts
markets.businessinsider.com - April 8 at 8:42 AM
TScan Therapeutics Appoints Louis As CMOTScan Therapeutics Appoints Louis As CMO
markets.businessinsider.com - April 8 at 8:42 AM
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical OfficerTScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
finance.yahoo.com - April 8 at 8:42 AM
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.
globenewswire.com - April 8 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ADMA Biologics logo

ADMA Biologics

NASDAQ:ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Adverum Biotechnologies logo

Adverum Biotechnologies

NASDAQ:ADVM
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Aptose Biosciences logo

Aptose Biosciences

NASDAQ:APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Immatics logo

Immatics

NASDAQ:IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
TScan Therapeutics logo

TScan Therapeutics

NASDAQ:TCRX
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.